Articles

Informa teams up with Saama on trials

Aim is to leverage AI to offer customers a complete understanding of the clinical trial landscape
Written byMel J. Yeates
| 3 min read

LONDON—In February, Citeline, part of Informa Pharma Intelligence’s suite of pharmaceutical, medtech and biomedical research and analysis solutions, and Saama Technologies Inc., a clinical analytics company, announced a partnership to integrate Citeline’s application programming interfaces (APIs) with Saama’s artificial intelligence (AI) and deep-learning solutions.

The goal of this strategic agreement is to bridge global clinical data and real-world data to improve both planning for and conducting clinical trials. Joint customers reportedly will gain “unparalleled insight into robust clinical trial intelligence” with greater efficiency than before.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Abstract illustration of colorful spectral emission peaks.
As flow cytometry panels grow larger and more complex, thoughtful panel design has become critical for experimental success.
A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.